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Purpose
This study analyzed the outcomes of patients with resected extrahepatic bile duct cancer
(EHBDC) in order to clarify the role of adjuvant treatments in these patients.
Materials and Methods
A total of 336 patients with EHBDC who underwent curative resection between 2001 and
2010 were analyzed retrospectively. The treatment types were as follows: surgery alone
(n=168), surgery with chemotherapy (CTx, n=90), surgery with radiotherapy (RT) alone
(n=29), and surgery with chemoradiotherapy (CRT, n=49).
Results
The median follow-up period was 63 months. The 5-year rates of locoregional failure-free
survival (LRFFS), distant metastasis-free survival (DMFS), progression-free survival (PFS),
and overall survival (OS) for all patients were 56.5%, 59.7%, 36.6%, and 42.0%, respectively.
In multivariate analysis, surgery with RT and CRT was a significant prognostic factor for
LRFFS, and surgery with CTx was a significant prognostic factor for DMFS, and surgery with
CTx, RT, and CRT was a significant prognostic factor for PFS (p < 0.05). Surgery with CTx
and CRT showed association with superior OS (p < 0.05), and surgery with RT had marginal
significance (p=0.078). In multivariate analysis of the R1 resection patients, surgery with
CRT showed significant association with OS (p < 0.05).
Conclusion
Adjuvant RT and CTx may be helpful in improving clinical outcomes of patients with resected
EHBDC who have a high risk of disease recurrence, particularly R1 resection patients. Con-
duct of additional prospective, larger-scale studies will be required in order to confirm the
benefit of adjuvant RT and CTx in these patients.
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Introduction
Complete surgical resection is considered the only curative
modality for extrahepatic bile duct cancer (EHBDC) [1]. The
prognosis after curative resection without adjuvant treat-
ment is poor, with a reported 5-year survival rate of 12%-
54%, despite aggressive surgical procedures such as major
hepatectomy, pancreatoduodenectomy (Whipple’s proce-
dure), and extensive lymphadenectomy [1-3]. Treatment fail-
ures included locoregional failures or distant relapses or
both, and adjuvant radiotherapy (RT) and chemotherapy
(CTx) are considered to increase the rate of survival by 
improving locoregional disease and systemic control.
Due to its rarity, conduct of randomized controlled trials
for EHBDC is difficult [1,4]. Few randomized controlled tri-
als evaluating adjuvant treatment have been reported, and
most reports are retrospective analyses. Therefore, the role
of adjuvant therapy in resected EHBDC remains controver-
sial. Several reports suggested that adjuvant RT improved
survival [3,5-9]; however, others suggested that adjuvant RT
had no effect on survival [10,11]. Currently, there is no con-
sensus regarding patient selection for adjuvant RT and/or
CTx. 
The aim of the current study was to clarify the role of 
adjuvant treatment for patients with resected EHBDC by 
analyzing treatment outcomes, including overall survival
(OS) and identifying patterns of treatment failure, and prog-
nostic factors.
Materials and Methods
1. Study design and patients
We conducted a retrospective review of the medical reco-
rds of 382 patients with EHBDC adenocarcinoma who unde-
rwent curative surgical resection between January 2001 and
December 2010 at Severance Hospital or Gangnam Severance
Hospital in Seoul, Korea. The inclusion criteria were patho-
logically proven adenocarcinoma of EHBDC, no distant
metastasis, and an Eastern Cooperative Oncology Group per-
formance status of ! 2. Patients with carcinoma of the intra-
hepatic bile duct, gallbladder, or ampulla of Vater were
excluded from the study. Patients who experienced in-hos-
pital death (n=24), were lost to follow up after discharge
(n=13), and those with other concurrent malignancy (n=9)
were also excluded. Data from the remaining 336 patients
were analyzed retrospectively.
Disease stage was defined according to the sixth edition of
the American Joint Committee on Cancer (AJCC) system.
Among the perihilar bile duct cancer patients, N2 patients
were not included in this study, according to the AJCC sev-
enth edition. Tumor location was recorded as the perihilar
or distal bile duct. A perihilar duct tumor was defined
anatomically as being located in the extrahepatic biliary tree
proximal to the origin of the cystic duct. A distal bile duct
tumor was a tumor involving the common bile duct.
The routine procedure for patient evaluation included a
detailed history, physical examination, complete blood
count, liver function testing, carbohydrate antigen 19-9
(CA19-9) and carcinoembryonic antigen (CEA) levels, stan-
dard chest radiographs, endoscopic retrograde cholangiog-
raphy or magnetic resonance cholangiopancreatography,
abdominal and pelvic computed tomography (CT), and mag-
netic resonance imaging (MRI) and/or positron emission 
tomography–computed tomography (PET-CT). Biliary drai-
nage was performed in patients with hyperbilirubinemia
(total bilirubin > 2 mg/dL) or cholangitis symptoms caused
by impending obstructive jaundice (i.e., fever, leukocytosis,
and abdominal pain). 
Surgical resection procedures depended on primary tumor
location. Combined hepatic and hilar resection was per-
formed for perihilar bile duct tumors and pylorus-preserving
pancreatoduodenectomy for distal bile duct tumors. Bile
duct resection alone was performed in patients with limited
tumor extent, old age, comorbidity, or poor liver function.
All patients underwent lymph node (LN) dissection, and 18 
median LNs were removed.
All patients were followed-up at 1-month post-surgery
and then every 3-6 months. Patients were screened for CA19-
9, CEA, and underwent a biliary CT scan. When recurrent
disease was suspected, a MRI or PET-CT was performed for
confirmation. Recurrence was also confirmed pathologically
by biopsy, cytology, and/or radiological findings. 
2. Adjuvant treatment
Adjuvant treatment was determined according to the
physician’s discretion. Adjuvant CTx alone, adjuvant RT
alone, or adjuvant concurrent chemoradiotherapy (CRT) was
administered according to the physician’s preference.
The chemotherapeutic regimen was determined based on
the experience with various regimens at our institution. A
median of six cycles of 5-fluorouracil (5-FU) with cisplatin
(FP)–based or gemcitabine-based CTx was administered to
patients with adjuvant CTx alone. FP consisted of 5-FU 
administered at a dose of 1,000 mg/m2/day on days 1-3 and
cisplatin 70 mg/m2/day administered on day 1 every 4 weeks.
Gemcitabine was administered at 1,000 mg/m2 weekly.
Details of the patient profile for adjuvant RT have been 
described previously [12]. All patients underwent three-
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dimensional conformal RT, which was initiated 4-6 weeks
(median, 42 days) after resection. The clinical target volume
included the primary tumor bed with a 1- to 2-cm margin
and the regional lymphatics. The planning target volume 
included the clinical target volume and a uniform 0.5-cm
margin. RT treated multiple fields using megavoltage photon
beams (6 or 10 MV) at 1.8 Gy daily for 5 days/wk. All treat-
ment plans were determined individually, considering the
planning target volume and organs-at-risk (e.g., duodenum,
liver, and kidney). The median radiation dose was 50.4 Gy
(range, 41.4 to 54 Gy).
During RT, concomitant CTx was administered to patients
with CRT. Concomitant 5-FU–based or gemcitabine-based
CTx was administered according to the physician’s prefer-
ence. Two cycles of 5-FU (1,000 mg/m2/day) and leucovorin
(20 mg/m2/day) were administered for 3 days in the first
and last week of RT. Gemcitabine was administered at 1,000
mg/m2/wk during RT.
3. Statistical analyses
Survival was calculated from the date of surgical resection.
All events were measured from the date of surgery to the
date of recurrence. Locoregional recurrence was defined as
recurrence in the primary tumor bed and regional lymphatic
areas. Distant metastasis was defined as recurrence in a sys-
temic organ, the peritoneum, or distant LNs. Progression-
free survival (PFS) was the time from the date of surgical
resection until the first reported recurrence, or death. OS was
calculated from the date of surgical resection to the date of
death or the date of the last follow-up visit.
A chi-square test or Fisher exact test was used for compar-
ison of categorical variables between groups. Survival rates
were calculated using Kaplan-Meier methods and compared
using the log-rank test. Multivariate analysis was performed
using a Cox proportional hazards model and hazard ratio
with a 95% confidence interval for determination of prognos-
tic factors. Criteria for inclusion of variables in a multivariate
analysis included statistical significance in univariate analy-
sis and clinical relevance. A p-value of < 0.05 indicated sta-
tistical significance.
Results
1. Patient characteristics
The characteristics of the 336 patients are summarized in
Table 1. Enrollment included 243 patients (72.3%) from Sev-
erance Hospital and 93 patients (27.7%) from Gangnam Sev-
erance Hospital. The median age was 64 years old (range, 32
to 90 years). The primary tumor location was the distal bile
duct in 227 patients and perihilar in 109 patients. Seventy-
eight patients underwent bile duct resection alone, 165 unde-
rwent pylorus-preserving pancreatoduodenectomy, and 93
underwent bile duct resection with liver resection. R0 resec-
tion was achieved in 251 patients (74.7%); R1 resection, in 67
patients (19.9%); and R2 resection, in 18 patients (5.4%). 
Regional LN metastasis was found after LN dissection in 127
patients (37.8%). The patients were divided into four groups
according to the treatment types as follows: patients who 
underwent surgery alone without adjuvant treatment
(surgery alone, n=168), surgery followed by adjuvant CTx
alone (surgery with CTx, n=90), surgery followed by adju-
vant RT alone (surgery with RT, n=29), and surgery followed
by adjuvant CRT (surgery with CRT, n=49).
A comparison of the clinicopathological parameters 
according to treatment type is provided in Table 1. In surgery
with CRT bile duct resection was performed more fre-
quently, and R1 and R2 resection were more frequent in the
surgery with RT and CRT. Lymphovascular invasion and 
advanced stage LN positive cancers were more frequent in
the surgery with CTx group compared with the other groups.
Positive perineural invasion (PNI) was more frequent in the
surgery with CTx, RT, and surgery with CRT groups com-
pared with the surgery alone group II. The highest number
of stage IIA patients underwent surgery alone, while the
highest number of stage IIB patients underwent surgery with
CTx. Other clinicopathological characteristics were not sig-
nificantly different between the treatment groups.
2. Survival
The median follow-up period was 63 months (range, 3 to
155 months). Of the 336 patients, 137 (40.8%) survived at least
until the end of the follow-up period. The median OS was 46
months. The 5-year locoregional failure-free survival (LRFFS),
distant metastasis-free survival (DMFS), PFS, and OS rates
were 56.5%, 59.7%, 36.6%, and 42.0%, respectively.
3. Prognostic factors
Results of univariate analysis are summarized in Table 2,
which showed that preoperative and postoperative CA19-9
level, resection margin, histological grade, PNI, nodal status,
and overall stage were prognostic factors for LRFFS, DMFS,
PFS, and OS (p < 0.05). Tumor location, lymphovascular 
invasion, and T stage showed significant association with
DMFS, PFS, and OS (p < 0.05).
Results of multivariate analysis are summarized in 
Table 3. In multivariate analysis, postoperative CA19-9 level
of at least 37 U/mL, histological grade, and nodal status
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Table 1. Patient characteristics of all patients and comparison of subgroups (treatment type) using the chi-square test or
Fisher exact test
Characteristic Total Surgery alone Surgery with Surgery with Surgery with p-value(n=336) (n=168) CTx (n=90) RT (n=29) CRT (n=49)
Age (yr)
! 60 124 (36.9) 56 (33.3) 41 (45.6) 9 (31.0) 18 (36.7) 0.236
> 60 212 (63.1) 112 (66.7) 49 (54.4) 20 (69.0) 31 (63.3)
Sex
Male 216 (64.3) 118 (70.2) 51 (56.7) 16 (55.2) 31 (63.3) 0.115
Female 120 (35.7) 50 (29.8) 39 (43.3) 13 (44.8) 18 (36.7)
ECOG performance status 
0-1 323 (96.1) 163 (97.0) 87 (96.7) 28 (96.6) 45 (91.8) 0.406
2 13 (3.9) 5 (3.0) 3 (3.3) 1 (3.4) 4 (8.2)
Tumor location
Perihilar bile duct 109 (32.4) 55 (32.7) 24 (26.7) 13 (44.8) 17 (34.7) 0.318
Distal bile duct 227 (67.6) 113 (67.3) 66 (73.3) 16 (55.2) 32 (65.3)
Preoperative CA19-9 (U/mL)
< 37 105 (31.3) 61 (36.3) 22 (24.4) 9 (31.0) 13 (26.5) 0.217
" 37 231 (68.8) 107 (63.7) 68 (75.6) 20 (69.0) 36 (73.5)
Postoperative CA19-9 (U/mL)
< 37 281 (83.6) 143 (85.1) 75 (83.3) 21 (72.4) 42 (85.7) 0.377
" 37 55 (16.4) 25 (14.9) 15 (16.7) 8 (27.6) 7 (14.3)
Preoperative CEA (ng/mL)
< 5 297 (88.4) 153 (91.1) 74 (82.2) 27 (93.1) 43 (87.8) 0.160
" 5 39 (11.6) 15 (8.9) 16 (17.8) 2 (6.9) 6 (12.2)
Surgical procedure
Bile duct resection 78 (23.2) 32 (19.0) 11 (12.2) 10 (34.5) 25 (51.0) < 0.001
PPPD 165 (49.1) 85 (50.6) 54 (60.0) 10 (34.5) 16 (32.7)
Liver lobectomy with bile duct resection 93 (27.7) 51 (30.4) 25 (27.8) 9 (31.0) 8 (16.3)
Resection margin
R0 251 (74.7) 145 (86.3) 77 (85.6) 10 (34.5) 19 (38.8) < 0.001
R1 67 (19.9) 22 (13.1) 12 (13.3) 13 (44.8) 20 (40.8)
R2 18 (5.4) 1 (0.6) 1 (1.1) 6 (20.7) 10 (20.4)
Histologic grade
WD/MD 284 (84.5) 142 (84.5) 75 (83.3) 24 (82.8) 43 (87.8) 0.906
PD 52 (15.5) 26 (15.5) 15 (16.7) 5 (17.2) 6 (12.2)
Lymphovascular invasion
No 256 (76.2) 135 (80.4) 57 (63.3) 23 (79.3) 41 (83.7) 0.009
Yes 80 (23.8) 33 (19.6) 33 (36.7) 6 (20.7) 8 (16.3)
Perineural invasion
No 120 (35.7) 75 (44.6) 21 (23.3) 10 (34.5) 14 (28.6) 0.005
Yes 216 (64.3) 93 (55.4) 69 (76.7) 19 (65.5) 35 (71.4)
T stage 
T1-2 150 (44.6) 76 (45.2) 34 (37.8) 14 (48.3) 26 (53.1) 0.348
T3-4 186 (55.4) 92 (54.8) 56 (62.2) 15 (51.7) 23 (46.9)
N stage
N0 209 (62.2) 128 (76.2) 36 (40.0) 17 (58.6) 28 (57.1) < 0.001
N1 127 (37.8) 40 (23.8) 54 (60.0) 12 (41.4) 21 (42.9)
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showed significant association with LRFFS, DMFS, PFS, and
OS (p < 0.05). Preoperative CA19-9 level of at least 37 U/mL
showed significant association with DMFS, PFS, and OS 
(p < 0.05). R2 resection was a significant prognostic factor for
LRFFS, PFS, and OS (p < 0.05), and R1 resection showed sig-
nificant association with OS (p < 0.05). Lymphovascular 
invasion showed significant association with DMFS and PFS.
Surgery with CTx was a significant prognostic factor for
DMFS, PFS, and OS, and surgery with RT was a significant
prognostic factor for LRFFS and PFS (p < 0.05). Surgery with
CRT showed significant association with LRFFS, PFS, and OS
(p < 0.05). Surgery with RT showed a marginal association
with OS (p=0.078), and surgery with CRT showed correlation
with superior systemic control with marginal significance 
(p = 0.078).
4. Patterns of failure
The site of recurrence was evaluated in all patients over
the entire follow-up period (Table 4). Locoregional failure 
occurred in 149 patients (44.3%) and distant metastasis 
occurred in 162 patients (48.2%), of whom 103 had both 
locoregional recurrence and distant metastasis. Locoregional
recurrence was the first event in 131 patients (39.0%) and dis-
tant relapse occurred first in 121 patients (36.0%). The liver
was the most common site of primary metastatic recurrence
(61 patients). Distant failures occurred first at the peritoneal
cavity in 46 patients.
Patterns of failure were also analyzed in terms of the treat-
ment type. In the first and cumulative recurrence, surgery
with RT and CRT reduced the locoregional recurrence rate
with greater marginal significance than surgery alone and
surgery with CTx. In the first recurrence, the distant failure
rate of surgery with CTx and CRT was similar to that of sur-
gery alone, but showed reduced systemic progression with
marginal significance compared to surgery with RT (p=0.058).
The cumulative incidence of distant failure was similar 
between all groups regardless of treatment type. In patients
with perihilar bile duct cancers, surgery with RT and CRT
reduced locoregional failure (p < 0.05).
5. Subgroup analysis of the R1 resection patients
The first site of relapse was evaluated in R1 resection 
patients (Table 4). Locoregional failure occurred in 25 pati-
ents (37.3%) and distant metastasis in 30 patients (44.8%).
Surgery with RT and CRT reduced the locoregional failure
rate compared with surgery alone and surgery with CTx 
(p < 0.05), and surgery with CTx and CRT reduced the dis-
tant recurrence rate compared with surgery alone and sur-
gery with RT (p < 0.05).
In the univariate analysis, LRFFS, DMFS, PFS, and OS 
differed according to treatment types (Figs. 1-3). In multi-
variate analysis, surgery with RT and CRT showed signifi-
cant association with improved LRFFS and surgery with CTx
and CRT showed significant association with lengthened
DMFS (p < 0.05) (Table 5). Surgery with CRT was the signif-
icant factor for OS (p < 0.05).
Discussion
A total of 336 patients with EHBDC who underwent cura-
tive resection were analyzed retrospectively. Although treat-
ment type was not a significant factor for PFS and OS in
univariate analysis, in multivariate analysis, surgery with
CTx had a significant positive impact on DMFS, PFS, and OS,
and surgery with CRT prolonged LRFFS, PFS, and OS. 
Although the benefit of OS had borderline significance, sur-
gery with RT had LRFFS and PFS benefits. In the subgroup
Table 1. Continued
Characteristic Total Surgery alone Surgery with Surgery with Surgery with p-value(n=336) (n=168) CTx (n=90) RT (n=29) CRT (n=49)
Stage
I 105 (31.3) 64 (38.1) 13 (14.4) 10 (34.5) 18 (36.7) < 0.001
IIA 90 (26.8) 60 (35.7) 17 (18.9) 5 (17.2) 8 (16.3)
IIB 108 (32.1) 30 (17.9) 50 (55.6) 9 (31.0) 19 (38.8)
III 33 (9.8) 14 (8.3) 10 (11.1) 5 (17.2) 4 (8.2)
Values are presented as number (%). The p-value was calculated between the four groups by chi-square test or Fisher exact
test. CTx, chemotherapy; RT, radiotherapy; CRT, concurrent chemoradiotherapy; ECOG, Eastern Cooperative Oncology
Group; CA, carbohydrate antigen; CEA, carcinoembryonic antigen; PPPD, pylorus preserving pancreaticoduodenectomy;
WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated.
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Table 2. Univariate analysis of prognostic factors of LRFFS, DMFS, PFS, and OS
Prognostic factor No. of patients 5-Yr survival rate (%)
LRFFS p-value DMFS p-value PFS p-value OS p-value
Age (yr)
! 60 124 56.9 0.947 62.5 0.564 39.0 0.587 44.8 0.341
> 60 212 56.3 57.9 35.1 40.4
Sex
Male 216 58.0 0.701 60.0 0.750 38.3 0.512 42.5 0.897
Female 120 54.3 59.1 33.7 41.5
Tumor location
Perihilar bile duct 109 50.3 0.057 45.7 0.002 25.3 0.001 28.9 < 0.001
Distal bile duct 227 59.3 65.8 41.7 47.9
Preoperative CA19-9 (U/mL)
< 37 105 64.1 0.02 76.9 < 0.001 53.5 < 0.001 55.4 < 0.001
" 37 231 53.1 51.3 28.9 35.9
Postoperative CA19-9 (U/mL)
< 37 281 61.7 < 0.001 65.1 < 0.001 43.2 < 0.001 48.1 < 0.001
" 37 55 24.7 28.8 3.8 11.4
Preoperative CEA (ng/mL)
< 5 297 57.4 0.392 59.7 0.689 37.6 0.151 42.9 0.364
" 5 39 49.1 60.4 27.8 35.4
Resection margin
R0 251 61.0 < 0.001 64.6 0.018 41.6 0.004 47.1 0.001
R1 67 51.7 48.6 24.8 29.5
R2 18 8.9 29.0 5.6 11.9
Histologic grade
WD/MD 284 58.9 0.002 63.0 < 0.001 38.8 < 0.001 44.6 < 0.001
PD 52 43.4 40.3 24.8 27.9
Lymphovascular invasion
No 256 59.1 0.05 64.8 < 0.001 42.2 < 0.001 48.2 < 0.001
Yes 80 47.2 43.3 19.3 23.3
Perineural invasion
No 120 65.6 0.016 67.4 0.006 48.0 < 0.001 55.3 < 0.001
Yes 216 50.6 55.8 30.3 34.6
T stage
T1-2 150 60.0 0.120 66.8 0.003 41.8 0.009 49.2 0.004
T3-4 186 53.8 53.9 32.5 36.3
N stage
N0 209 61.8 0.001 67.5 < 0.001 45.6 < 0.001 51.8 < 0.001
N1 127 47.6 46.1 22.0 26.5
Stage
I 105 63.2 0.008 74.0 0.001 49.8 < 0.001 57.1 < 0.001
IIA 90 62.3 61.2 43.4 49.1
IIB 108 48.6 46.8 21.4 26.3
III 33 43.1 50.0 26.9 30.2
Treatment type
Surgery alone 168 57.5 0.139 60.9 0.056 39.1 0.346 43.2 0.596
Surgery with CTx 90 48.0 65.8 30.5 37.9
Surgery with RT 29 66.7 35.2 30.3 42.9
Surgery with CRT 49 64.2 59.6 44.0 47.6
LRFFS, locoregional failure-free survival; DMFS, distant metastasis-free survival; PFS, progression-free survival; OS, overall
survival; CA, carbohydrate antigen; CEA, carcinoembryonic antigen; WD, well differentiated; MD, moderately differentiated;
PD, poorly differentiated; CTx, chemotherapy; RT, radiotherapy; CRT, concurrent chemoradiotherapy.
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analyses of the R1 resection patients, the OS rates improved
significantly in the surgery with CRT group compared with
that in the other groups, suggesting that CRT has a greater
clinical benefit for these patients than for the other groups.
Patients with EHBDC who undergo curative resection
alone with 5-year OS rates < 55% have poor prognosis [1-3].
The locoregional recurrence and distant metastasis rates for
resected EHBDC have been reported as 38%-55% and 23%-
45% [3,13-15], similar to those reported here. With such high
rates after curative resection, adjuvant local and systemic
treatment should be considered in patients with EHBDC.
Our findings showed that adjuvants RT and/or CTx could
reduce the high incidence of recurrence and improve sur-
vival rates, especially for patients with R1 resection. There-
fore, patients with resected EHBDC with a high risk of
locoregional recurrence or distant metastasis, including R1
resection, would benefit from adjuvant treatment.
Locoregional recurrence can cause bile duct obstruction,
hepatic failure, recurrent sepsis, and subsequent mortality.
Despite conflicting results on the utility of adjuvant RT in 
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patients with EHBDC, several retrospective studies have
suggested an improvement in locoregional control and sur-
vival [3,5-9]. In the current study, in patients undergoing 
adjuvant RT or CRT, the first recurrence event was locore-
gional in eight patients (27.6%) and 14 patients (28.6%), 
respectively, similar to that reported in other studies (17%-
24%) [3,5,7,8,16,17]. The current study found that LRFFS and
OS rates in the surgery with CRT group were significantly
better than those in the surgery alone group, suggesting that
adjuvant RT may increase OS by improving locoregional dis-
ease control.
To date a substantial survival benefit of CTx in patients
with resected cholangiocarcinoma has not been demon-
strated [1]. However, in a randomized trial conducted by
Takada et al. [18], patients who received CTx following cur-
ative resection tended to have better OS rates than patients
who did not receive CTx (41% vs. 28%), although the differ-
ence was not significant. In addition, Murakami et al. [2]
found that adjuvant CTx might improve the OS of patients
with extrahepatic cholangiocarcinoma with PNI. Lim et al.
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[19] found that adjuvant CRT followed by adjuvant CTx pro-
longed OS compared with CRT alone in patients with cura-
tively resected EHBDC. These results suggested that
adjuvant CTx might have partial benefit in treatment of
EHBDC by controlling microscopic residual tumor growth.
One limitation of this research is that when adjuvant treat-
ment was administered, it could not be confirmed which
treatment, among adjuvant CTx, adjuvant RT, and adjuvant
CRT, had a greater benefit. In the case of adjuvant RT, there
were only 29 patients, thus the interpretation of the results
was limited; however, although adjuvant RT reduced the 
locoregional recurrence, the distant relapse rate showed a 
relatively increase, thus it is considered to have shown mar-
ginal significance in OS benefit. In the case of adjuvant CTx,
the locoregional relapse was higher than in adjuvant RT or
CRT. It is interpreted that this eventually caused distant fail-
ure, so that the cumulative distant recurrence rate became
similar to that of the other treatment groups. Although the
evidence presented herein was insufficient, simultaneous
performance of adjuvant RT and CT is considered capable of
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also simultaneously reducing locoregional relapse and sys-
temic failure. Particularly in the case of the patient who 
underwent R1 resection, adjuvant CRT actually caused 
simultaneous reduction of the locoregional relapse and the
systemic recurrence. Accordingly, simultaneous adjuvant RT
and CTx could have a benefit in slowing disease progression.
The completeness of surgical resection and whether or not
regional LN metastasis is present are the most important
prognostic factors for determining survival in patients 
undergoing curative resection [2,3,6-8,13,14,16]. Likewise, we
also found that resection margin and N stage were significant
prognostic factors for OS. In the current and other studies
higher T stage, poorly differentiated tumor, lymphovascular
invasion positive, PNI positivity, and pre and postoperative
CA19-9 level of at least 37 U/mL have been identified as
prognostic factors [2,3,8,12-15,17]. Adjuvant RT and/or CTx
seems to improve the outcome of patients with one or many
of these risk factors.
There are some limitations to our study. The study was
nonrandomized and retrospective in nature, and unrecog-
nized biases could not be considered. Prognostic factors, such
as stage and resection margin, did not show equal distribu-
tion between the treatment groups. The selection of treat-
ment methods was based on physician decision. The RT
volume and radiation dose, and the CTx regimen were also 
determined according to the physician’s preference. There-
fore, heterogeneous treatments might be a confounding fac-
tor.
Conclusion
Adjuvant treatments were important prognostic factors
after curative resection of EHBDC. Adjuvant RT and CTx
may reduce locoregional recurrence and distant metastasis,
consequently improving survival. Therefore, we recommend
adjuvant RT and CTx for patients with EHBDC at high risk
for recurrence. However, further randomized prospective
studies are needed to clarify the role of adjuvant treatment
in patients with EHBDC treated with curative resection.
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